Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Breast cancer chemotherapy induces vascular dysfunction and hypertension through a NOX4-dependent mechanism
Piotr Szczepaniak, … , David G. Harrison, Tomasz J. Guzik
Piotr Szczepaniak, … , David G. Harrison, Tomasz J. Guzik
Published May 26, 2022
Citation Information: J Clin Invest. 2022;132(13):e149117. https://doi.org/10.1172/JCI149117.
View: Text | PDF
Research Article Vascular biology

Breast cancer chemotherapy induces vascular dysfunction and hypertension through a NOX4-dependent mechanism

  • Text
  • PDF
Abstract

Cardiovascular disease is the major cause of morbidity and mortality in breast cancer survivors. Chemotherapy contributes to this risk. We aimed to define the mechanisms of long-term vascular dysfunction caused by neoadjuvant chemotherapy (NACT) and identify novel therapeutic targets. We studied arteries from postmenopausal women who had undergone breast cancer treatment using docetaxel, doxorubicin, and cyclophosphamide (NACT) and from women with no history of such treatment matched for key clinical parameters. We explored mechanisms in WT and Nox4–/– mice and in human microvascular endothelial cells. Endothelium-dependent, NO-mediated vasodilatation was severely impaired in patients after NACT, while endothelium-independent responses remained normal. This was mimicked by a 24-hour exposure of arteries to NACT agents ex vivo. When applied individually, only docetaxel impaired endothelial function in human vessels. Mechanistic studies showed that NACT increased inhibitory eNOS phosphorylation of threonine 495 in a Rho-associated protein kinase–dependent (ROCK-dependent) manner and augmented vascular superoxide and hydrogen peroxide production and NADPH oxidase activity. Docetaxel increased expression of the NADPH oxidase NOX4 in endothelial and smooth muscle cells and NOX2 in the endothelium. A NOX4 increase in human arteries may be mediated epigenetically by diminished DNA methylation of the NOX4 promoter. Docetaxel induced endothelial dysfunction and hypertension in mice, and these were prevented in Nox4–/– mice and by pharmacological inhibition of Nox4 or Rock. Commonly used chemotherapeutic agents and, in particular, docetaxel alter vascular function by promoting the inhibitory phosphorylation of eNOS and enhancing ROS production by NADPH oxidases.

Authors

Piotr Szczepaniak, Mateusz Siedlinski, Diana Hodorowicz-Zaniewska, Ryszard Nosalski, Tomasz P. Mikolajczyk, Aneta M. Dobosz, Anna Dikalova, Sergey Dikalov, Joanna Streb, Katarzyna Gara, Pawel Basta, Jaroslaw Krolczyk, Joanna Sulicka-Grodzicka, Ewelina Jozefczuk, Anna Dziewulska, Blessy Saju, Iwona Laksa, Wei Chen, John Dormer, Maciej Tomaszewski, Pasquale Maffia, Marta Czesnikiewicz-Guzik, Filippo Crea, Agnieszka Dobrzyn, Javid Moslehi, Tomasz Grodzicki, David G. Harrison, Tomasz J. Guzik

×

Figure 1

Effects of breast cancer neoadjuvant chemotherapy using docetaxel, cyclophosphamide, and doxorubicin (NACT) on vascular function.

Options: View larger image (or click on image) Download as PowerPoint
Effects of breast cancer neoadjuvant chemotherapy using docetaxel, cyclo...
(A) Study design of human blood vessel collection in patients with breast cancer without NACT (No NACT) or after 6 ± 3 courses of NACT prior to surgery. (B) Representative examples of endothelium-dependent vasorelaxations in response to increasing concentrations of ACh (1 nM–10 μM) in arteries from patients with or without NACT. (C) Average endothelium-dependent vasorelaxation responses to ACh (1 nM–10 μM) and endothelium-independent relaxation responses to SNP (1 nM–10 μM) in arteries from patients without NACT (n = 55) and with NACT (n = 40). Two rings were studied per patient, and the values were averaged. Data are expressed as the mean ± SEM. ****P < 0.0001 versus no NACT (C, left); *P < 0.05 versus no NACT (C, right); 2-way, repeated-measures ANOVA. (D) Experimental design of an ex vivo organ culture study of the effects of NACT on vascular function in NACT-naive arteries. (E) Endothelium-dependent (ACh) and endothelium-independent (SNP) vasorelaxations in NACT-naive arteries after a 24-hour organ culture with the combined NACT components docetaxel (100 nM), 4-hydroperoxycyclophosphamide (4-HC) (10 nM), and doxorubicin (100 nM) or vehicle (Veh, solvent) (paired arterial rings for each treatment; n = 7 patients). *P < 0.05 versus vehicle; 2-way, repeated-measures ANOVA. (F) Effects of individual components of NACT on endothelium-dependent (ACh) and endothelium-independent (SNP) vasorelaxations in NACT-naive arteries after a 24-hour organ culture with either docetaxel (100 nM), cyclophosphamide (100 nM), doxorubicin (100 nM), or vehicle (solvent) (paired vessel rings for each treatment; n = 5). *P < 0.05 versus vehicle; 2-way, repeated-measures ANOVA with Tukey’s test. Data in E and F are expressed as the mean ± SEM. DTX, docetaxel; DOX, doxorubicin; CP, cyclophosphamide; Phe, phenylephrine.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts